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Background: Alterations in lipid metabolism are inherent to the metabolic transformations that support tumorigenesis.
The relationship between the synthesis, storage and use of lipids and their importance in cancer is poorly understood.
The human group X secreted phospholipase A2 (hGX sPLA2) releases fatty acids (FAs) from cell membranes and
lipoproteins, but its involvement in the regulation of cellular FA metabolism and cancer is not known.
Results: Here we demonstrate that hGX sPLA2 induces lipid droplet (LD) formation in invasive breast cancer cells,
stimulates their proliferation and prevents their death on serum deprivation. The effects of hGX sPLA2 are shown to be
dependent on its enzymatic activity, are mimicked by oleic acid and include activation of protein kinase B/Akt, a cell
survival signaling kinase. The hGX sPLA2-stimulated LD biogenesis is accompanied by AMP-activated protein kinase
(AMPK) activation, up-regulation of FA oxidation enzymes and the LD-coating protein perilipin 2, and suppression of
lipogenic gene expression. Prolonged activation of AMPK inhibited hGX sPLA2-induced LD formation, while etomoxir,
an inhibitor of FA oxidation, abrogated both LD formation and cell survival. The hGX sPLA2-induced changes in lipid
metabolism provide a minimal immediate proliferative advantage during growth under optimal conditions, but they
confer to the breast cancer cells a sustained ability to resist apoptosis during nutrient and growth factor limitation.
Conclusion: Our results identify hGX sPLA2 as a novel modulator of lipid metabolism that promotes breast cancer cell
growth and survival by stimulating LD formation and FA oxidation.
Keywords: Secreted phospholipase A2, Breast cancer, Cell survival, Apoptosis, Lipid droplets, Fatty acid oxidation,
Lipid signaling, Etomoxir, Carnitine palmitoyltransferase 1, AMP-activated protein kinaseBackground
Tumor cells display progressive, oncogene-driven alter-
ations in the metabolic pathways that supply energy and
biosynthetic intermediates to enable their survival,
growth and proliferation [1]. At the core of this meta-
bolic reprogramming is a shift towards macromolecular
biosynthesis, based largely on the use of mitochondrial
metabolites as anabolic precursors, and supported by
changes in lipid synthesis, degradation and signaling
[2-4]. The attainment of a lipogenic phenotype, charac-
terized by the increased dependence of cancer cells on
de novo fatty acid (FA) synthesis, is typical of many can-
cer cells [2]. The transformed properties of tumor cells* Correspondence: toni.petan@ijs.si
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reproduction in any medium, provided the orcan also depend on lipolytic remodeling [3,5] and FA oxi-
dation [6-10]. The biochemical mechanisms governing the
transformations of lipid metabolism in cancer cells, in par-
ticular the relationships between lipid synthesis, storage
and use, and their importance in the neoplastic process
are still largely unknown. Identifying the factors respon-
sible for the modulation of lipid metabolism and signaling
in cancer is important for understanding the disease and
for devising more rational preventive and therapeutic
approaches.
Secreted phospholipases A2 (sPLA2s) are lipolytic en-
zymes that act on membrane glycerophospholipids to
liberate free FAs (FFAs) and lysophospholipids by catalyz-
ing the hydrolysis of their sn-2 ester bond [11]. These low-
molecular mass, disulfide-rich and Ca2+-dependent
enzymes are secreted from a variety of cells and act in
autocrine or paracrine manners on cell membranes andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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particles, surfactant and dietary lipids, microbial mem-
branes and microvesicles [12]. The nine active sPLA2 en-
zymes known in humans display different tissue expression
patterns and specific enzymatic preferences for binding to
different types of phospholipid membranes, suggesting dis-
tinct biological roles for each sPLA2 [13,14]. The multitude
of cellular effects of the released FAs and lysophos-
pholipids, and of their numerous bioactive metabolites,
further explain their involvement in a variety of physio-
logical processes and diseases, including lipid digestion
and remodeling, acute and chronic inflammatory diseases,
cardiovascular diseases, reproduction and host defense
against infections [12]. Recent studies have implicated vari-
ous sPLA2s in cancer and metabolic disorders [15].
Aberrant expression of various sPLA2s in cancer cells
has been associated with the pathology of colorectal,
breast, gastric and prostate cancers [16,17]. The most
studied group IIA sPLA2 has been proposed to have a
pro-tumorigenic role in prostate [18] and esophageal
cancer [19], but an anti-tumorigenic role in gastric can-
cer [20]. Its role in colorectal cancer is still controversial
[12,16,21,22]. The involvement of sPLA2s in cancer and
other diseases has been investigated in relation to their
ability to release arachidonic acid (AA) from cell mem-
branes and stimulate, either directly or in coordination
with the cytosolic group IVA PLA2 (cPLA2α), the pro-
duction of eicosanoids, including the mitogenic prosta-
glandin E2 (PGE2) [12,14,23]. Several studies have
suggested a tumor-promoting role for the group III and
X sPLA2s in colorectal cancer, based on their ability to
stimulate PGE2 synthesis and cell proliferation [24,25].
However, the human group X (hGX) sPLA2 stimulates
colon cancer cell proliferation by a mechanism that is
dependent on the released FFAs and lysophospholipids,
but not on its potent stimulation of PGE2 synthesis [26].
The underlying mechanisms of the action of hGX sPLA2
and other sPLA2 enzymes in different cancers are not
known and confirmation of their functional contribution
to tumorigenesis awaits further studies.
The group X sPLA2 displays the greatest potency among
mammalian sPLA2s in hydrolyzing the phosphatidylcho-
line (PC)-rich extracellular leaflet of mammalian plasma
membranes and of lipoprotein particles [12,13]. Besides
AA, the enzyme also releases numerous other monoun-
saturated and polyunsaturated FFAs, which could influ-
ence lipid metabolism and tumorigenesis in a variety of
ways [3,7,12,27,28]. FFAs can be remodeled into mem-
brane phospholipids, catabolized through mitochondrial
FA oxidation or esterified into triacylglycerols (TAGs) and
stored in lipid droplets (LDs) [29-31]. Several enzymes
regulating FFA availability through synthesis, such as fatty
acid synthase (FAS) and acetyl-CoA carboxylase (ACC)
[2], and through lipolysis [3,5] have been clearly associatedwith cancer. In addition, there is increasing evidence for
an important role for mitochondrial FA oxidation in
tumorigenesis [6,8-10]. Interestingly, several recent reports
have revealed that group X sPLA2 affects lipid metabolism
in various physiological and pathophysiological settings,
including steroid hormone synthesis in adrenal glands
[32], lipid digestion in the gut and diet-induced obesity
[33]. Its recently proposed role in adipogenesis in mice
has been associated with down-regulation of the expres-
sion of several genes important for lipid synthesis and
adipogenesis, including sterol regulatory element-binding
protein-1 (SREBP-1) and FAS [34]. Additionally, the group
X sPLA2 hydrolyzes serum low-density lipoprotein (LDL)
and stimulates lipid accumulation and foam cell formation
from macrophages [12]. The possible associations between
sPLA2s and basic lipid metabolism, such as fatty acid oxi-
dation and synthesis, TAG synthesis and lipolysis, in the
context of cell fate and tumorigenesis have, however, not
been explored.
Altered lipid metabolism, including lipogenesis, β-
oxidation and phospholipid remodeling, contributes to
the transformed phenotype of breast cancer [2,4,35].
The involvement of sPLA2s in breast cancer has not
been studied, and there are only a few reports correlat-
ing the increased expression of group IIA sPLA2 with
advanced cancer and decreased patient survival [17,36].
The aim of this study was to determine whether hGX
sPLA2 affects breast cancer cell growth and survival, and
to delineate the underlying mechanism of action. We
show for the first time that hGX sPLA2 induces LD for-
mation in the highly tumorigenic MDA-MB-231 breast
cancer cells in an enzyme activity-dependent manner,
thereby stimulating cell proliferation and significantly
prolonging cell survival under serum deprivation-induced
stress. Our results suggest that FFAs, in particular oleic
acid (OA), released from membrane phospholipids by the
action of hGX sPLA2, are in large part responsible for LD
biogenesis and cell survival. We also demonstrate that the
mechanism of hGX-induced cell survival and lipid accu-
mulation is associated with alterations in the expression of
key lipogenic and β-oxidation enzymes, and modulation of
AMP-activated protein kinase (AMPK) and protein B/Akt
kinase signaling pathways. The pro-tumorigenic effects in-
duced by hGX sPLA2 were abolished by etomoxir,
suggesting a critical role for β-oxidation in hGX-induced
LD formation and cell survival in breast cancer cells.
Results
hGX sPLA2 stimulates proliferation and prolongs
serum-free survival of MDA-MB-231 cells in an enzyme
activity-dependent manner
In order to determine whether hGX sPLA2 affects the
growth of breast cancer cells, we measured the prolifera-
tion rate of MDA-MB-231 cells treated with hGX sPLA2.
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lated the proliferation of quiescent, serum-deprived
MDA-MB-231 cells (Figure 1A). The effect was com-
pletely abolished by the sPLA2 inhibitor varespladib
[37,38], suggesting a dependence on sPLA2 enzyme activ-
ity. Importantly, the enzyme also displayed a mitogenic ef-
fect at sub-nanomolar concentrations in proliferating
MDA-MB-231 cells grown in the presence of 10% FBS
(Additional file 1: Figure S1A). To confirm the depend-
ence on enzymatic activity of hGX-induced stimulation of
cell proliferation, we treated starved MDA-MB-231 cells
with a range of concentrations of recombinant wild-type
mouse group X (mGX) sPLA2 and with its active site mu-
tant mGX H48Q that possesses less than 0.1% of the wild-
type enzyme activity [26]. The use of the mouse ortholog
of hGX sPLA2 is justified since both enzymes display very
similar enzymatic characteristics on cell membranes and
mitogenic activities on colon cancer cells [13,26]. TheFigure 1 hGX sPLA2 stimulates the proliferation and prevents serum wi
activity-dependent manner. After serum deprivation for 48 h (A) or 24 h (B
serum-free medium containing 0.1% FAF BSA for 24 h (A) or 96 h (B) in the p
concentration of 50 μM. MDA-MB-231 cells grown for 24 h in complete cultur
encoding the wild-type hGX or catalytic-site mutant hGX(H48Q) (C, D). The ce
of varespladib for an additional 48 h (C). Alternatively, the cells were washed a
containing 0.05% FAF BSA for an additional 96 h (D). Breast cancer cell lines w
as described in Methods, and treated with 10 nM recombinant hGX in the pre
determined using the EdU incorporation assay on fixed cells with additional 7
cell cycle. Cell death (B, D, E) was analyzed using the TMRM/YO-PRO-1 assay
apoptotic) cells within the population was used for final analyses. The resultin
duplicate. Results that are statistically significant over control samples are indic
Bonferroni adjustment).results (Additional file 1: Figure S1B) confirm the role of
enzyme activity in the mitogenic effect of the group X
sPLA2 enzyme, since mGX sPLA2 induced a similar in-
crease in the rate of cell proliferation as the human en-
zyme, whereas its catalytically inactive H48Q mutant did
not induce significant changes in MDA-MB-231 cell pro-
liferation. The inability of the mutant to stimulate cell pro-
liferation also excludes a potential mitogenic action of a
low-level contaminating agent, such as lipopolysaccharide
(LPS), which may be present in bacterially expressed re-
combinant sPLA2s.
Since the positive effect of hGX sPLA2 on MDA-MB-
231 cell proliferation was more prominent when the cells
were serum-starved, we questioned whether the apparent
mitogenic effect of hGX sPLA2 could be the result of an
increase in cell survival under conditions of serum and
nutrient limitation. Indeed, when MDA-MB-231 cells
were serum-starved for 24 h and then incubated withthdrawal-induced cell death of breast cancer cells in an enzymatic
) MDA-MB-231 cells were treated with recombinant hGX (10 nM) in
resence or absence of the sPLA2 inhibitor varespladib (Var) at a final
e medium were transiently transfected with empty vector and plasmids
lls were then cultured in complete medium in the presence or absence
t 24 h post-transfection, and incubated in serum-free medium
ere exposed to prolonged serum-deprivation without medium renewal,
sence or absence of 50 μM varespladib (E). Cell proliferation (A, C) was
-AAD staining for accurate quantification of cells in the S-phase of the
and the percentage of TMRM negative and YO-PRO-1 positive (late
g values are means ± SD of at least two experiments performed in
ated (*, P < 0.05; **, P < 0.01; ***, P < 0.001; one-way ANOVA with
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without medium renewal for the next 96 h, there was a
2-fold reduction in the percentage of late apoptotic cells
in treated cells relative to untreated controls (Figure 1B)
and a corresponding 2-fold increase in the number of
healthy adherent cells (Additional file 1: Figure S1C). This
robust anti-apoptotic effect was completely prevented by
inhibition of the enzyme with varespladib, suggesting that
the ability of hGX sPLA2 to prevent MDA-MB-231 cell
death during prolonged serum withdrawal is dependent
on the products of its hydrolysis. Together, the above re-
sults using exogenously added sPLA2 show that hGX
sPLA2 can act from the extracellular milieu to exert a pro-
survival effect via its enzymatic activity.
Exogenously added and ectopically expressed sPLA2s
may act by different mechanisms, leading to different
cellular responses [14]. In contrast to the recombinant
enzyme, natural hGX is glycosylated in mammalian cells
and releases FFAs from intracellular membranes during
its secretion [39]. To confirm that cell-derived hGX
sPLA2 also has a positive effect on MDA-MB-231 cell
growth and/or survival, we performed gain-of-function
experiments by transiently expressing hGX sPLA2 and
its catalytically inactive H48Q mutant. The expression
and secretion of active hGX sPLA2 protein from transi-
ently transfected cells was confirmed with a highly sensi-
tive enzymatic assay using [3H]-labeled E. coli membranes
[39]. Sub-nanomolar amounts of the enzyme ranging from
0.2 nM to 0.5 nM (corresponding to 10–40 ng/106 cells)
in the period 24–72 h after transfection were secreted in
the extracellular medium from cells grown both in the
presence and absence of serum (Additional file 2: Table S2).
Most of the enzyme was secreted from the cells, since only
about 1% of total hGX sPLA2 was detected in cell lysates
72 h after transfection (data not shown). Cells transiently
expressing hGX sPLA2 displayed higher proliferation rates
(Figure 1C) and were significantly more resistant to serum
withdrawal-induced cell death (Figure 1D) than control
cells. The mitogenic and the pro-survival effects were not
observed in cells expressing the H48Q mutant of hGX
sPLA2 and were completely abrogated by addition of the
sPLA2 inhibitor varespladib to the culture media. It is im-
portant to emphasize that hGX sPLA2, both secreted from
transfected MDA-MB-231 cells and the exogenously
added recombinant protein (Additional file 1: Figure S1A),
was biologically active at very low subnanomolar to nano-
molar concentrations, which correspond to the putative
endogenous concentrations of hGX sPLA2 suggested from
the amounts determined in mouse tissues (0.3 nM in sera
and 1–10 ng mGX/mg tissue protein; [40]). Thus, transi-
ently expressed hGX sPLA2 is secreted from MDA-MB-
231 cells in an active form and, through the products of its
phospholipolytic activity, it stimulates cell proliferation and
confers resistance to serum withdrawal-induced cell death.Since sPLA2s may have opposing effects on cell
growth in different cancer cells [17], we next asked
whether hGX also prevents cell death in other breast
cancer cells with different tumorigenic properties. Inter-
estingly, hGX sPLA2 did not significantly affect the sur-
vival of the non-tumorigenic basal MCF-10A cells or of
the weakly tumorigenic, estrogen receptor (ER) positive
luminal MCF7 cells (Figure 1E). Further, it displayed a
slight negative effect on the survival of the ER negative
and HER2 positive SK-BR-3 cells. A weak, but statisti-
cally significant pro-survival effect, similar to that ob-
served in the basal ER negative MDA-MB-231 cells, was
observed in the weakly tumorigenic, ER positive luminal
T-47D cells. Thus, hGX sPLA2 displays a differential
ability to protect breast cancer cells from cell death, and
of the cell lines tested, the effect was most prominent in
the most tumorigenic and highly invasive triple negative
MDA-MB-231 cell line.
hGX sPLA2 prevents serum withdrawal-induced cell death
by stimulating LD formation in MDA-MB-231 cells
One of the most important observations from our flow
cytometry analyses of MDA-MB-231 cells treated with
hGX sPLA2 was the significant augmentation of cell
granularity, inferred from the increase in the side scatter
(SSC) parameter (Additional file 3: Figure S2). Such
changes in cell morphology can be the result of exten-
sive accumulation of neutral lipid in LDs, cytoplasmic
organelles present in almost all cell types [31]. LDs not
only store triglycerides and cholesterol esters to provide
fuel and biosynthetic substrates, but can also prevent
lipotoxicity and affect cell metabolism, growth and sur-
vival [3,31]. OA is a known inducer of LD formation in
various cell types. It is also one of the most abundant
FFAs incorporated into PC in cell membranes, including
those of MDA-MB-231 cells [41], and is one of the
major products of hGX sPLA2 activity on mammalian
cells [12]. Importantly, exogenously added OA has been
shown to induce LD accumulation in MDA-MB-231
cells, stimulate proliferation in serum-free media and
prevent cell death induced by serum withdrawal [27,42].
Thus, we speculated that the pro-survival effect of hGX
sPLA2 may be associated with LD formation stimulated
by FFAs, including OA, released by hGX sPLA2 enzym-
atic hydrolysis of breast cancer cell membranes. In fact,
recombinant hGX sPLA2 induced a gradual enzymatic
activity-dependent increase in LD content in serum-
starved MDA-MB-231 cells (Figures 2A and 2B) during
the 96 h survival experiment (Figure 1B). The induction
of LD formation was much more significant in prolifer-
ating MDA-MB-231 cells, as evidenced by flow cytome-
try and fluorescence microscopy analyses of Nile red
stained cells (Figures 2C and 2D). The hGX-induced in-




Figure 2 hGX induces TAG synthesis and LD formation in MDA-MB-231 cells in an enzymatic activity-dependent manner. (A) Quiescent
MDA-MB-231 cells were treated with recombinant hGX (10 nM) in serum-free medium and neutral lipid accumulation was determined at
indicated time points, using Nile red staining and flow cytometry. (B) Quiescent MDA-MB-231 cells were treated with hGX (10 nM) for 96 h in
serum-free medium in the presence or absence of varespladib (Var; 50 μM) and stained with Nile red. (C) MDA-MB-231 cells were grown in
complete culture medium in the presence of different concentrations of hGX and stained with Nile red at the indicated time points. (D) MDA-MB-231
cells were grown in complete culture medium in the presence of hGX (1 nM) for 48 h and TAG content was determined in cell lysates as described in
Methods. The TAG content of hGX-treated cells was significantly higher than in that of control cells (**, P = 0.0086; Student’s t-test). (E) MDA-MB-231
cells were grown in complete culture medium in the presence of hGX (1 nM) for 48 h. The cells were fixed, stained with Nile red to visualize LDs
(green) and DAPI to visualize nuclei (blue). The image shown is representative of two experiments. Values on the graphs are means ± SD of at least
two independent experiments performed in duplicate. Results that are statistically significant over control samples are indicated (**, P < 0.01;
***, P < 0.001; one-way ANOVA with Bonferroni adjustment).
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demonstrating that hGX stimulates TAG synthesis and in-
corporation into LDs. The higher level of hGX-induced
LDs in proliferating cells than in serum-starved, quiescent
cells is in line with the predominant anabolic metabolism
[1,4] and the higher availability of phospholipid substrates
for hGX sPLA2 in proliferating cells, including cell mem-
branes and serum lipoproteins [12,43]. Most of the LD
formation in proliferating MDA-MB-231 cells occurred
within the first 24 h of treatment and the level of accumu-
lated LDs reached maximal values after 48 h of incubation
with the enzyme (Figure 2C). This could explain the mod-
est and saturable positive effect of hGX on MDA-MB-231
cell proliferation in serum-containing media (Additional
file 1: Figure S1A) and its augmentation on serum-
deprived cells (Figure 1A).
The energy and building blocks stored in LDs during
growth in serum may be used gradually by the cell to sup-
port cell growth and survival depending on its needs [3]. It
was thus reasonable to investigate whether hGX-inducedLDs accumulated in proliferating cells would provide a
survival advantage to the cells on serum withdrawal and
removal of the enzyme. To this end, MDA-MB-231 cells
were treated with hGX sPLA2 for 48 h in the presence of
serum (LD accumulation phase), and the lipid content and
cell survival then measured during the subsequent 96 h
period of serum-free incubation in the absence of sPLA2
and without medium renewal (LD consumption phase).
The LDs formed by the action of hGX sPLA2 were con-
sumed during the subsequent serum starvation phase
(Figure 3A) and, importantly, the cells, which now
contained large amounts of pre-formed LDs, displayed a
remarkable survival rate even in the absence of the en-
zyme (Figure 3B).
To strengthen the proposal that LDs are responsible
for the effects of hGX on breast cancer cell survival, we
next investigated whether the differential ability of hGX
sPLA2 to stimulate cell survival in different breast cancer
cells (Figure 1E) corresponds to its LD-inducing potency
in a particular cell line. While hGX was observed to
Figure 3 LDs formed by the action of hGX convey a survival advantage to MDA-MB-231 cells during serum deprivation. (A) MDA-MB-231
cells were grown in complete culture medium in the presence of hGX for 48 h (1 nM). The cells were washed, sPLA2-free and serum-free medium
containing 0.02% BSA was added, and the cells incubated further without medium renewal. Neutral lipid content was measured by Nile red staining at
the indicated time points during starvation. Note that LD content gradually decreased during serum-starvation and that cells that contained pre-
formed hGX-induced LDs displayed an increased survival rate after 96 h of serum-starvation, as determined by the TMRM/YO-PRO-1 apoptosis assay
(B). (C) Breast cancer cell lines were grown in complete culture medium with hGX (10 nM) in the presence or absence of varespladib (Var; 50 μM) for
24 h and cellular LD content was measured by Nile red staining. Values on the graphs are means ± SD of at least two experiments performed in
duplicate and results that are statistically significant over control samples are indicated (*, P < 0.05; ***, P < 0.001; one-way ANOVA with
Bonferroni adjustment).
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MDA-MB-231 and T-47D cells (Figure 3C), which were
both protected from cell death by hGX during starvation
(Figure 1E), it induced only a modest increase in LD for-
mation in MCF7 cells and did not affect their survival
upon serum withdrawal. A lipogenic phenotype has been
suggested for MDA-MB-231 cells, but not for MCF7
cells, indicating that the ability of hGX sPLA2 to induce
LDs is dependent on the capacity of a particular cell line
to synthesize and store large amounts of TAGs [42,44].
These results strongly support the proposal that the LDs
formed due to the enzymatic action of hGX sPLA2, in
both rapidly proliferating and quiescent cells, are re-
sponsible for the increased survival of breast cancer cells
during serum deprivation. Clearly, rather than conferring
an immediate proliferative advantage to the cells grown
under optimal conditions, hGX-induced changes in lipid
accumulation are associated with a pro-survival, anti-
apoptotic mechanism that is triggered under conditions
of nutrient and growth factor limitation.
The ability of hGX sPLA2 to hydrolyze PC-rich membranes
is important for the stimulation of LD formation and its
pro-survival action
The different human and venom sPLA2s exhibit specific
and subtle substrate preferences towards phospholipid
head groups and acyl chains at the sn-2 position, which
result from their distinct membrane-binding affinities to
various phospholipid interfaces and also from subtle dif-
ferences in their active sites [13,45,46]. Since hGX sPLA2
is known for its high binding affinity and efficient hy-
drolysis of PC-rich cell membranes [12,45], we assumed
that its potency in inducing LD formation and cell sur-
vival in MDA-MB-231 cells could depend on thisproperty. Accordingly, two other sPLA2s with similarly
high affinities for PC-rich surfaces coupled with the abil-
ity to release FFAs from mammalian cells, the human
group V (hGV) sPLA2 [13] and the ammodytoxin A
(AtxA) V31W mutant, a neurotoxic snake venom sPLA2
[46], induced significant LD formation and protected
MDA-MB-231 cells from starvation-induced cell death
in an enzymatic activity-dependent manner (Figures 4A
and 4B). In contrast, the human group IIA enzyme,
which does not bind well to or hydrolyze the PC-rich
plasma membranes of mammalian cells [45], did not in-
duce LD formation or support cell survival. Thus, the
ability of an sPLA2 to bind with high affinity and
hydrolyze cell membrane phospholipids is essential for
the induction of LD formation and for breast cancer cell
survival. These results provide an additional proof that
the hydrolytic products released from MDA-MB-231 cell
membranes by hGX sPLA2 are responsible for the for-
mation of LDs, which in turn confer resistance to serum
withdrawal-induced apoptosis.
Oleic acid is an important mediator of hGX-induced
LD formation and cell survival in MDA-MB-231 breast
cancer cells
It has been shown that exogenously added OA and other
monounsaturated FAs induce LD formation and stimu-
late the growth and survival of various cells, including
breast cancer cells [27,29]. Furthermore, short-term ex-
posure of MDA-MB-231 cells to high micromolar con-
centrations of exogenous OA leads to accumulation of
TAG, increased lipolysis and a long-term resistance to
serum withdrawal-induced apoptosis [42]. The patterns
of lipid accumulation (Figure 3C) and of cell survival
changes (Figure 1E) induced by hGX sPLA2 are very
Figure 4 The effects of hGX are reproduced by other
PC-hydrolyzing sPLA2s. (A) Quiescent MDA-MB-231 cells were
treated with the indicated concentrations of recombinant hGIIA, hGV
and AtxA(V31W) in combination with varespladib (Var; 50 μM) in
serum-free medium for 96 h. Cellular neutral lipid content was then
determined by Nile red staining (A) and the percentage of apoptotic
cells within the population was measured in parallel samples by the
TMRM/YO-PRO-1 assay (B). The hGV and AtxA(V31W) sPLA2s, similar to
hGX in their ability to hydrolyze PC-rich membranes [13,46], induced
LD formation and prolonged cell survival in an enzymatic activity-
dependent manner, while hGIIA did not induce LD formation or
prolong survival. Values on the graphs are means ± SD of three
experiments performed in duplicate. Results that are statistically
significant over control samples are indicated (**, P < 0.01; ***,
P < 0.001; one-way ANOVA with Bonferroni adjustment).
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stimulated TAG synthesis and protected MDA-MB-231
and T-47D, but not MCF7 and MCF-10A, cells from
serum starvation-induced cell death [42]. This suggests
that the effects of hGX sPLA2 may be mediated by OA.
We next confirmed that OA is readily released from the
membranes of adherent MDA-MB-231 cells by hGX
sPLA2 (Additional file 4: Figure S3) and demonstrated
that exogenously added OA and recombinant hGX
sPLA2 display similar abilities to induce LD formation in
the three cell lines tested (Figure 5A). In contrast to
hGX sPLA2, however, OA prevented cell death only in
MDA-MB-231 cells (Figure 5B). This lack of a pro-
survival effect of OA in T-47D cells, despite their rela-
tively high levels of LDs, indicates that other sPLA2
hydrolytic products are involved in the anti-apoptotic
activity of hGX, in particular in T-47D cells. Since Hardy
et al. have shown [27,28,47] that OA stimulates MDA-
MB-231 cell proliferation by activating the phos-
phatidylinositol 3-kinase (PI3K)/Akt pathway, we askedwhether hGX also activates Akt kinase. In fact, both
hGX and OA increased the level of Akt phosphorylation
at Ser-473 in starved MDA-MB-231 cells (Figure 5C).
Interestingly, the dynamics of Akt activation were differ-
ent with hGX maximally activating Akt after 30 min,
while OA was less effective and reached a similar level
only after 2 h of incubation (Figure 5D). Nevertheless,
this supports the idea that OA mediates, at least in part,
the effects of hGX sPLA2 and that activated Akt sup-
ports the anti-apoptotic and metabolic alterations caused
by hGX sPLA2 [1]. Clearly, OA, as one of the most
abundant FAs released from cell membranes by the ac-
tion of hGX, may be one of the dominant lipid media-
tors of the effects of hGX on MDA-MB-231 cells by
being the major FFA feeding the pathway of TAG syn-
thesis and LD formation and also triggering pro-survival
signaling.
We have shown previously that hGX sPLA2 releases a
complex mixture of mitogenic products from colon can-
cer cells, including AA, OA and linoleic acid, lysophos-
phatidic acid (LPA), and eicosanoids [26]. To assess the
involvement in the effects of hGX sPLA2 of several sig-
naling pathways activated by these products [23,47], we
tested a range of pharmacological inhibitors for their
ability to interfere with hGX-induced LD formation
and survival. The cPLA2α inhibitors AZ-1 [48] and
pyrrolidine-2 did not suppress the stimulating effect of
hGX on LD formation in proliferating cells (Additional
file 5: Figure S4A). Pyrrolidine-2 increased both basal
and hGX-induced LD formation and was slightly toxic
to starving MDA-MB-231 cells, but did not affect the
pro-survival activity of hGX (Additional file 5: Figure S4B).
The non-selective cyclooxygenase (COX) inhibitor indo-
methacin only slightly inhibited LD formation, but did
not affect hGX-induced cell survival (Additional file 4:
Figures S3A and S3B). The mammalian target of rapa-
mycin (mTOR) pathway may be activated by PI3K/Akt
signaling, as well as by AA [49], to alter lipid metabolism
and stimulate anabolic growth in breast cancer cells
[50]. The mTOR inhibitor rapamycin marginally re-
duced hGX-induced LD formation (Additional file 5:
Figure S4A), indicating that mTOR may participate in,
but is not critical for, hGX-induced LD formation. Fi-
nally, results with two inhibitors of the autotaxin
(ATX)-LPA axis, S32826 and BrP-LPA [51,52] (Additional
file 5: Figure S4A), indicate that LPA signaling is not ne-
cessary for the effects of hGX. These results, therefore,
suggest that, while cPLA2α activity and the ATX-LPA
axis are not involved in the effects of hGX, COX-
mediated AA-metabolism and mTOR signaling may
contribute to, but are not critical for, the LD-promoting
and pro-survival activities of hGX in MDA-MB-231
cells. These results further strengthen the suggestion
that, of the various hydrolytic products released by
30 min 1 h 2 h 4 h
OA
hGX +- - +- - +- - +- -







Figure 5 Recombinant hGX sPLA2 and OA activate the pro-survival Akt kinase and display similar effects in breast cancer cells. (A, B)
MDA-MB-231, T-47D and MCF7 cell lines were grown in serum-free medium for 96 h in the presence of the indicated concentrations of OA
complexed with 0.5% FAF BSA. LD content was determined by Nile red staining (A) and cell death was assessed in parallel samples using the
TMRM/YO-PRO-1 apoptosis assay (B). (C) MDA-MB-231 cells were made quiescent by 48 h serum starvation, then washed and incubated with
hGX (10 nM) or OA (100 μM) in serum-free medium for the times indicated. Cell lysates were analyzed for the presence of Ser473-phosphorylated
Akt (p-Akt) kinase, total Akt protein and β-actin loading control by immunoblotting. The amount of p-Akt was normalized to total Akt protein and
was quantified relative to untreated controls at each specific time point (D). Values on the graphs are means ± SD of at least two experiments
performed in duplicate and results that are statistically significant over control samples are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001;
one-way ANOVA with Bonferroni adjustment).
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http://www.molecular-cancer.com/content/12/1/111hGX sPLA2 from cell membranes, OA plays a very im-
portant role in LD formation, lipid metabolism alter-
ations and pro-survival signaling in MDA-MB-231
breast cancer cells.Etomoxir suppresses hGX-induced LD accumulation and
cell survival in serum-starved MDA-MB-231 cells
It has been shown recently that β-oxidation contributes
to tumorigenesis [35,53] and may protect cancer cells
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it has been suggested that it complements LD accumula-
tion as a mechanism of preventing lipotoxicity in cells
exposed to high levels of exogenous FAs [31]. We there-
fore hypothesized that β-oxidation could be important
for cell survival in hGX-treated cells and that it may
contribute through either one or both of the following
mechanisms: β-oxidation of FFAs released by sPLA2
membrane hydrolysis and/or liberated from LDs through
lipolysis. We therefore sought to determine whether
pharmacological modulators of β-oxidation would affect
the positive effects of hGX on MDA-MB-231 cell survival
and LD formation. Etomoxir is an irreversible inhibitor of
carnitine palmitoyltransferase 1 (CPT1), the rate-limiting
enzyme in β-oxidation that transports activated FAs acrossFigure 6 Etomoxir, an inhibitor of β-oxidation, suppresses hGX-induc
cells were treated with hGX (10 nM) in serum-free medium containing 0.02
20 μM) and bezafibrate (Bez; 500 μM). Etomoxir, but not bezafibrate, prevente
231 cells were grown in complete medium for 24 h and then treated with hG
either etomoxir (20 μM) or bezafibrate (500 μM). Etomoxir significantly reduce
stimulated control LD formation (#, P < 0.05) and supported hGX-induced LD
for 48 h in complete medium to form LDs; the cells were then washed (0 h) a
in the presence or absence of either etomoxir (250 μM) or bezafibrate (500 μM
compared with those at the beginning of starvation (0 h). Both agents signific
cells were treated as described in (D) and the percentage of apoptotic cells d
μM) alone significantly increased the percentage of apoptotic cells in samples
graphs are means ± SD of at least two experiments performed in duplicate. R
***, P < 0.001; one-way ANOVA with Bonferroni adjustment).the mitochondrial membrane [54]. It effectively suppresses
β-oxidation in various cells and tissues [6,9,54], including
MDA-MB-231 breast cancer cells [28]. Remarkably, when
MDA-MB-231 cells were incubated for 96 h in serum-free
medium in the presence of low, non-toxic concentrations
of etomoxir (20 μM), the increase in LD accumulation
(Figure 6A) and the anti-apoptotic activity (Figure 6B and
Additional file 6: Figure S5) of hGX sPLA2 were com-
pletely abolished. This strengthens the above conclusions
that the prolonged survival of serum-deprived MDA-MB-
231 cells is dependent on the hGX-induced LDs. Surpris-
ingly, without affecting the levels of neutral lipids in
control cells, etomoxir significantly reduced accumulation
of LDs in well-fed, proliferating MDA-MB-231 cells
treated with hGX for 48 h (Figure 6C), when β-oxidationed LD biogenesis and cell survival. (A, B) Quiescent MDA-MB-231
% FAF BSA for 96 h in the presence or absence of etomoxir (Eto;
d both hGX-induced LD formation (A) and cell survival (B). (C) MDA-MB-
X (1 nM) in complete medium for 48 h in the presence or absence of
d the level of hGX-induced LDs in proliferating cells, while bezafibrate
formation. (D, E) MDA-MB-231 cells were pre-treated with hGX (10 nM)
nd incubated in serum-free and hGX-free medium for an additional 48 h
). The levels of LDs remaining after serum deprivation (48 h) were
antly prevented LD breakdown during starvation (D). (E, F) MDA-MB-231
etermined following 48 h (E) or 96 h (F) serum deprivation. Etomoxir (250
with preformed LDs, and also in hGX-untreated cells (E). Values on the
esults that are statistically significant are indicated (*, P < 0.05; **, P < 0.01;
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etomoxir treatment typically leads to a compensatory in-
crease in TAG accumulation [54], presumably reflecting
an attempt of the cell to minimize the lipotoxicity of accu-
mulating FFAs in the cytosol [31]. This suggests that
etomoxir may also suppress the pro-survival action of
hGX in starved cells by reducing hGX-induced LD forma-
tion. To confirm that β-oxidation is critical for cell sur-
vival enabled by hGX-induced LDs, we tested the ability
of etomoxir to alter the survival of serum-deprived
MDA-MB-231 cells that actively consume pre-formed
LDs (Figure 3A) and in which β-oxidation is presumably
highly active. LD breakdown was effectively blocked by
etomoxir (Figure 6D), even leading to increased levels of
neutral lipids, indicating that, by blocking β-oxidation,
etomoxir also suppressed LD lipolysis and that any add-
itional FFAs are channeled towards TAG synthesis [55].
Importantly, etomoxir not only abolished the positive ef-
fect of LDs on cell survival, but also induced cell death in
both control cells and in cells with pre-formed droplets
(Figure 6E), strongly suggesting that β-oxidation is neces-
sary for cell survival during starvation. Thus, while non-
toxic concentrations of etomoxir suppressed hGX-induced
LD formation and cell survival in quiescent cells, higher
concentrations of the inhibitor prevented LD consump-
tion and abolished their anti-apoptotic effect when added
to cells with pre-formed LDs.
On the other hand, bezafibrate, a pan-peroxisome
proliferator-activated receptor (PPAR) agonist and an ac-
tivator of mitochondrial biogenesis and β-oxidation
[3,6,56], did not affect hGX-induced accumulation of
LDs or cell survival in starved cells (Figures 6A and 6B),
but caused a slight increase in both basal and hGX-
induced LD accumulation levels in proliferating cells
(Figure 6C). During the LD consumption phase in cells
with pre-formed LDs, bezafibrate suppressed LD break-
down, even inducing further accumulation of LDs in
both control and hGX-treated cells, but did not prevent
the pro-survival effect of the LDs (Figures 6D and 6F).
Accordingly, besides stimulating mitochondrial biogen-
esis and β-oxidation, including the expression of CPT1
[54], PPARα activation has also been shown to induce
TAG accumulation [57]. Thus, bezafibrate stimulates LD
accumulation and effectively prevents net LD breakdown
in starving MDA-MB-231 cells, but does not block
hGX-induced LD formation or cell survival, most prob-
ably due to its ability to stimulate β-oxidation as well.
This is in line with the suggestion that active β-
oxidation contributes to LD formation and is necessary
for cell survival in hGX-treated MDA-MB-231 cells. Col-
lectively, the results of these experiments using pharma-
cological modulators of FA metabolism confirm that the
pro-survival effect of hGX in MDA-MB-231 cells de-
pends on its ability to stimulate LD formation. They alsosupport a hypothesis that β-oxidation contributes to the
process of hGX-induced LD biogenesis in MDA-MB-231
cells, regardless of their metabolic and proliferative sta-
tus, and is critical for the effect of hGX-induced LDs on
cell survival during starvation.
hGX sPLA2 alters the expression of major lipid
metabolism genes
Since our results suggest that the pro-survival effect of
hGX in MDA-MB-231 cells depends on neutral lipid ac-
cumulation and β-oxidation, we sought whether hGX
may affect the expression of major lipid metabolism and
LD-associated genes. Using qPCR, we analyzed the ex-
pression of a set of 38 selected genes involved in FA acti-
vation (ACSL1, ACSL3, ACSL4, ACSL5, ACSL6), FA
oxidation (CPT1A, ACADL, ACADVL, HADHA, HADHB)
and synthesis (ACACA, ACACB, FASN, SCD), TAG syn-
thesis (GPAM, GPAT2, AGPAT6, AGPAT9, DGAT1,
DGAT2) and lipolysis (PNPLA2, MGLL), cholesterol me-
tabolism (HMGCR, SOAT1, CAV1), LD-associated pro-
teins (PLIN1, PLIN2, PLIN3, PLIN4, PLIN5, CIDEB), lipid
metabolism transcription factors (SREBF1, PPARA,
PPARG, RXRB), lysophosphatidylcholine (LPC) esterifica-
tion (LPCAT1, LPCAT2) and FA uptake (SCL27A1). No
alterations in the expression levels of these genes were
found in serum-deprived MDA-MB-231 cells treated with
hGX for 96 h (data not shown). However, there were
significant changes in the expression of several genes
(Figure 7A) when MDA-MB-231 cells were treated with
hGX for 48 h in the presence of serum to induce max-
imal LD biogenesis (Figure 2C), then serum-deprived for
24 h in the absence of hGX to allow high levels of LD
lipolysis (Figure 3A). Eight time-points were analyzed to
search for possible correlations between the time-course
of net LD accumulation in proliferating cells and LD
consumption in starved cells with changes in gene ex-
pression. A significant decrease was detected in the ex-
pression of genes for the lipogenic transcription factor
sterol regulatory element-binding protein 1 (SREBP-1)
and the key FA synthesis enzymes ACC1, FAS and
stearoyl-CoA desaturase 1 (SCD-1) [2,4,29] (Figure 7A).
Small but significant decreases were also detected for
the long-chain acyl-CoA synthetase 3 (ACSL3) and the
hydroxymethylglutaryl-coenzyme A reductase (HMGCR)
enzymes. Interestingly, changes in the expression of most
of the lipogenic genes were first observed at the 48 h
time-point, when MDA-MB-231 cells had typically accu-
mulated their maximal level of LDs, but were greatest
12 h after the cells were switched to serum-free media.
The basal expression of the genes encoding for FAS,
SCD-1 and SREBP-1 was elevated at these time-points,
suggesting that hGX acts on MDA-MB-231 cells to sup-
press their induction, most probably due to a rising need
for de novo lipid synthesis. On the other hand, there was
Figure 7 hGX alters the expression levels of genes involved in lipid metabolism. MDA-MB-231 cells were grown in complete culture
medium in the presence of hGX (1 nM) for 48 h. The medium was removed and cells were washed and incubated for an additional 24 h in
serum-free and hGX-free medium containing 0.02% FAF BSA. Cell lysates were prepared at the time points indicated and the relative expression
levels of genes involved in lipid metabolism were determined by means of qPCR (A). The relative protein expression levels of ACC1 and VLCAD
were analyzed by immunoblotting (B) at the indicated time-points. (C) Protein band intensities were analyzed by densitometry and normalized
to loading control (β-actin) values at each time-point. Values on the graphs are means ± SD of three experiments performed in duplicate and
results that are statistically significant over control samples are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001; one-way ANOVA with
Bonferroni adjustment).
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oxidation enzymes, CPT1A and very long-chain acyl-
CoA dehydrogenase (VLCAD) – the first enzyme in the
β-oxidation cycle [58]. In contrast to the lipogenic genes,
the expression of the two β-oxidation genes was aug-
mented by hGX after only 24 h of cell growth and was
further increased at the beginning of the starvation
period. Interestingly, there was no alteration in the basal
expression levels of these genes, suggesting that their ex-
pression is not regulated by serum deprivation. Further-
more, the mRNA level of the LD-coating protein
perilipin 2 (PLIN2; Figure 7A), that promotes LD forma-
tion and regulates lipolysis in different cells [3,57,59],
was also higher in hGX-treated cells. Its mRNA levelswere significantly elevated after only 12 h of incubation
of proliferating MDA-MB-231 cells with hGX; they
reached maximal levels 6 h after serum withdrawal and
decreased steadily over the final 18 h of starvation,
suggesting a correlation between the amount of LDs and
perilipin 2 mRNA levels in MDA-MB-231 cells. The
hGX-induced alterations in gene expression were con-
firmed at the protein level for the first enzymes in FA
synthesis and β-oxidation, ACC1 and VLCAD, respect-
ively, corroborating the qPCR results (Figures 7B and 7C).
Collectively, these results strongly suggest that prolifer-
ating MDA-MB-231 cells respond to the products of
hGX phospholipolysis first by up-regulating perilipin 2,
which supports LD formation [3], followed very closely
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enzymes, CPT1 and VLCAD, suggesting an augmentation
of the rates of β-oxidation [60]. When the amount of ac-
cumulated LDs reaches its maximal levels (Figure 2C),
and after serum withdrawal, when LDs are rapidly con-
sumed (Figure 3A), the induction of the expression of
lipogenic genes, in particular the ones encoding SREBP-1,
ACC1, FAS and SCD, is significantly repressed, while ex-
pression of the key β-oxidation enzymes, CPT1 and
VLCAD, reaches maximal levels. Clearly, the hGX-
induced LD accumulation in MDA-MB-231 cells is ac-
companied by significant changes in the expression of
major lipid metabolism genes, indicative of an increase in
β-oxidation and LD formation, as well as a reciprocal de-
crease in de novo FA and cholesterol synthesis.
hGX-induced LD formation is associated with activation
of AMPK
AMPK is a central metabolic sensor and reciprocal regu-
lator of cellular metabolism. It blocks anabolic and acti-
vates energy producing processes in response to low
energy states of the cell [61]. Activation of AMPK in-
creases β-oxidation and TAG lipolysis [62] and inhibits
FA and TAG synthesis [61,63]. Importantly, AMPK in-
creases cancer cell growth and survival during energy
stress by altering FA metabolism [6,8,60]. An increase in
the amount of Thr172-phosphorylated AMPKα (p-AMPKα)
in proliferating MDA-MB-231 cells was observed after
48 h of growth in the presence of recombinant hGX
sPLA2 or exogenous OA (Figures 8A and 8B). This
showed that the effects of hGX on LD formation and
cell survival are associated with the activation of AMPK.
In line with their ability to suppress hGX-induced LD
formation (Figures 6C and Additional file 5: Figure S4A),
etomoxir and the non-selective ACS inhibitor triacsin C
prevented the increase in p-AMPKα levels induced by
hGX. Bezafibrate, on the other hand, increased the basal
level of activated AMPK and hGX did not further ele-
vate p-AMPKα levels, in keeping with its effects on LD
formation (Figure 6C). These results suggest that the
levels of p-AMPKα correlate with the amount of hGX-
induced LDs. In support of this, LD accumulation
reached peak levels after 48 h in hGX-treated proliferat-
ing MDA-MB-231 cells (Figure 2C), suggesting that the
increase in AMPK activation may be a consequence of
extensive TAG synthesis and LD formation [29]. These
results therefore point to the effects of hGX on LD forma-
tion and cell survival being associated with a regulatory
mechanism involving AMPK. Further, timely activation of
AMPK, leading to blockade of LD formation may be cru-
cial for preventing excessive energy consumption in rap-
idly proliferating MDA-MB-231 cells treated with hGX.
To substantiate this view, we asked whether prolonged ac-
tivation of AMPK would prevent the LD formationinduced by hGX. Activating AMPK with the AMP-analog
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR)
[6] (Figures 8A and 8B) completely abolished hGX-
induced LD formation in both proliferating (Figure 8C)
and in starved MDA-MB-231 cells (Figure 8D), indicating
that AMPK activation indeed blocks hGX-induced LD
biogenesis. This is in line with the complete blockade of
lipid synthesis caused by AICAR in MDA-MB-231 cells
[64]. It further raised the question as to whether the sup-
pression of LD biogenesis by AICAR would abolish the
positive effect of hGX on cancer cell survival during
serum deprivation. We found that prolonged treatments
with AICAR reduced the basal level of dying cells in the
starving MDA-MB-231 cell population to a level similar
to that observed with hGX itself (Figure 8E), thus effect-
ively masking the positive effect of hGX. The effect of
AICAR accords with the recently reported role for AMPK
in enabling cancer cell survival during energy stress by
suppressing lipogenesis and activating β-oxidation [6,8]. It
is therefore also consistent with the proposed importance
of hGX-induced alterations in FA metabolism for the sur-
vival of hGX-treated MDA-MB-231 cells. Thus, prolonged
activation of AMPK by AICAR in MDA-MB-231 cells
prevents hGX-induced lipid accumulation by blocking LD
biogenesis in both proliferating and starved cells, sug-
gesting that the role of AMPK may indeed be to suppress
TAG synthesis and LD formation in hGX-treated cells.
Discussion
We have demonstrated here that hGX sPLA2-mediated
phospholipid hydrolysis induces LD formation and alters
lipid metabolism in triple negative breast cancer cells,
stimulating their proliferation and prolonging cell sur-
vival during serum deprivation. Several mammalian
sPLA2s have been shown to stimulate cell proliferation
in cancer cells [18,19,22,25]. An anti-apoptotic role in
growth factor-deprived cells has been shown for the
group IIA in kidney fibroblasts [65], and for the group
III and X sPLA2s in neuronal cultures [66,67]. The enzym-
atic activity-dependent mechanisms reported [18,22,65]
have usually been associated with the pleiotropic actions
of AA-derived eicosanoids [25] and rarely with lysophos-
pholipids [26,66]. The involvement of signaling pathways
triggered by sPLA2 receptors on the cell surface has been
also suggested in some cases [68,69]. However, the exact
molecular mechanisms involved in the effects of sPLA2 on
cell fate have not been elucidated nor has the relevance of
these activities in mammalian pathophysiology been delin-
eated [14]. This is not surprising given the differential tis-
sue expression patterns of sPLA2s, the vast variety of
extracellular target membranes and the plethora of bio-
active products that are released from cell membranes in
response to the action of sPLA2s [12,26]. hGX sPLA2 has
been shown to induce colon cancer cell proliferation by
- OA
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Figure 8 hGX-induced LD accumulation is associated with activation of AMPKα. (A) MDA-MB-231 cells were treated with OA (100 μM) and
hGX (1 nM) in complete culture medium for 48 h in the presence of etomoxir (Eto; 20 μM), triacsin C (TrC; 2 μM), AICAR (500 μM) or bezafibrate
(Bez; 500 μM). Free OA was incubated in complete culture medium for 1 h before addition to the cells. Cell lysates were analyzed for the
presence of Thr172-phosphorylated AMPKα (p-AMPKα), total AMPKα and β-actin loading control by immunoblotting and densitometry. The
amounts of p-AMPKα obtained from three separate experiments were normalized to total AMPKα protein levels and quantified relative to
untreated controls (B). (C) Cells were treated as in (A). Prolonged incubation (48 h) of proliferating MDA-MB-231 cells with AICAR (500 μM)
abolished the hGX-induced (1 nM) LD formation. Cellular LD content was determined by Nile red staining. (D, E) Serum-starved MDA-MB-231
cells were treated with hGX (10 nM) in serum-free medium containing 0.02% FAF BSA for 96 h in the presence or absence of AICAR (500 μM).
After 96 h, cellular LD content was determined by Nile red staining, showing that AICAR prevented hGX-induced LD formation (D). Cell survival
was assessed with the TMRM/YO-PRO-1 apoptosis assay, indicating that AICAR alone has a pro-survival effect in MDA-MB-231 cells, thus
effectively masking the positive effect exerted by hGX. Values on the graphs are means ± SD of at least two experiments performed in duplicate
and results that are statistically significant over control samples are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001; one-way ANOVA with
Bonferroni adjustment).
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pholipids and eicosanoids, but, surprisingly, the prolifera-
tive effects of hGX sPLA2 were not dependent on the
mitogenic activity of AA-derived prostaglandin or LPC-derived LPA signaling [26]. Information about the possible
involvement of sPLA2s in the modulation of cellular me-
tabolism, rather than direct bioactive lipid signaling, is
only beginning to emerge [15]. Here we show that hGX
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duces significant alterations in fatty acid metabolism and
storage in breast cancer cells. These changes result pri-
marily in prevention of serum withdrawal-induced cell
death rather than in stimulation of cell proliferation. The
previously reported mitogenic effects of sPLA2s in colon
cancer and other cells were also modest [18,19,22,25,26],
suggesting that the positive effects of sPLA2s on cell pro-
liferation could, at least in some of these studies, be in fact
a consequence of underlying changes in basic lipid metab-
olism and a pro-survival action, which is most evident
under stressful conditions for the cell.
Several lines of evidence demonstrate that the effects of
hGX sPLA2 on breast cancer cells are dependent on its
enzymatic activity. First, the effects of recombinant hGX
sPLA2 on MDA-MB-231 cell proliferation (Figure 1A), cell
survival (Figure 1B) and LD formation (Figure 2B) were
prevented by the potent sPLA2 inhibitor varespladib.
Secondly, it also prevented the effects of ectopically
expressed hGX sPLA2. The transient expression of its
catalytically impaired H48Q mutant did not affect MDA-
MB-231 cell proliferation or survival upon serum with-
drawal (Figures 1C and 1D). Further, the fact that
varespladib, an inhibitor with low cell membrane perme-
ability, completely prevents the actions of exogenous and
ectopically expressed hGX argues for an extracellular ac-
tion of the enzyme. Thirdly, while the potency of the re-
combinant mGX sPLA2 to stimulate cell proliferation
was similar to that of the human enzyme, its H48Q mu-
tant did not induce a significant change in MDA-MB-231
cell proliferation rate (Additional file 1: Figure S1B).
Fourthly, two other sPLA2 enzymes, hGV sPLA2 [13] and
a neurotoxic snake venom sPLA2, AtxA(V31W) [46], each
with high activity on mammalian cell membranes, pre-
vented cell death and induced LD formation in a
varespladib sensitive manner. The hGV sPLA2 enzyme
was less effective than hGX in inducing these cellular ef-
fects, which is consistent with previous results showing a
better ability of the latter enzyme to act on plasma mem-
branes of mammalian cells and release free FAs, such as
arachidonic acid [13,45]. In contrast, the hGIIA sPLA2 en-
zyme, known for its inability to bind to PC-rich mem-
branes and act on intact mammalian cells [45], was unable
to induce LD formation or prevent MDA-MB-231 cell
death. These facts lead to the conclusion that the LD for-
mation and prevention of cell death induced by hGX in
MDA-MB-231 cells are dependent on the ability of hGX
to bind to and hydrolyze phospholipid membranes.
Numerous studies have shown that hGX sPLA2 is the
most potent of the mammalian sPLA2 enzymes in
hydrolyzing PC-rich phospholipid vesicles, plasma mem-
branes and lipoprotein particles, thus releasing large
amounts of lysophospholipids and unsaturated FAs, in-
cluding oleic, linoleic and arachidonic acids [12,13,26,43].Thus, lipoprotein particles are an important target for
hGX sPLA2 hydrolysis during cell culture in the presence
of serum; however, the major source of lipid for hGX-
induced LD generation in serum-deprived cells must be
the cell membranes of MDA-MB-231 cells. hGX sPLA2
may act directly on the plasma membrane of the cells
and/or on microvesicles being actively released and
recycled by MDA-MB-231 cells [70], as well as on apop-
totic cells during starvation [71]. Regardless of the source
of lipid, the results of this study indicate that of the prod-
ucts typically released upon hGX sPLA2 membrane hy-
drolysis OA is largely responsible for the metabolic and
signaling alterations that support its pro-tumorigenic
effects. Exogenous OA is known to induce a PI3K/
Akt-dependent proliferation, stimulate LD formation
and prevent serum withdrawal-induced apoptosis in
MDA-MB-231 cells [27,28,42,47]. hGX sPLA2 is shown in
the present work to stimulate cell proliferation and in-
crease the survival of serum-deprived MDA-MB-231 cells
(Figures 1A and 5C and 5D). Further, exogenous hGX and
OA are both shown to activate AMPK in proliferating
cells (Figures 8A and 8B), strongly suggesting that OA is
one of the major mediators of the pro-tumorigenic effects
of hGX. Importantly, the effects of OA are not restricted
to breast cancer cells, since there is ample evidence that
OA feeds into the TAG synthesis pathway and stimulates
LD formation, cell growth and survival in different non-
adipose cells, even channeling saturated FAs to TAGs to
prevent their apoptotic effects [31,55]. In cells exposed to
excess lipids, the removal of FFAs through increased TAG
accumulation and β-oxidation appears to be a general cel-
lular response to the lipotoxic effects of FA overload [31].
Thus, besides promoting TAG synthesis, OA also pre-
vented palmitate-induced apoptosis in skeletal muscle
cells by stimulating β-oxidation through elevation of the
expression of CPT1, activation of AMPK and repression
of the activity of ACC [72]. Similarly, hGX significantly in-
creased the levels of two important β-oxidation enzymes,
CPT1A and VLCAD, in MDA-MB-231 cells (Figure 7), in
parallel with the high rate of LD formation, activation of
AMPK (Figures 8A and 8B) and suppression of the induc-
tion of lipogenic enzymes, including ACC1 (Figure 7).
Nevertheless, it is highly likely that, besides OA, other
products of hGX phospholipid hydrolysis contribute to its
effects in breast cancer cells, either by feeding metabolic
pathways or by triggering cell signaling to various degrees
[73]. Our results indicate that cPLA2α activation and LPA
signaling (Additional file 5: Figure S4) are not important
for the effects of hGX on MDA-MB-231 cells. However,
the ability of rapamycin and indomethacin to partially
suppress hGX-induced LD formation points to a pos-
sible role for AA in supporting LD formation through
mTOR activation [49] and COX-dependent prostaglan-
din synthesis, respectively. Nevertheless, the contribution
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lipid metabolism induced by hGX sPLA2 in MDA-MB-
231 cells is clearly minimal. Altogether, the results
presented in this study suggest that FFAs, in particular
OA, liberated from membrane phospholipids by the en-
zymatic activity of hGX sPLA2 are responsible for the
observed alterations in lipid metabolism and the pro-
survival effects induced by hGX in MDA-MB-231 breast
cancer cells.
LDs, the intracellular neutral lipid storehouses until
recently regarded as inert energy depots, are now
regarded as complex organelles not only involved in the
metabolic regulation of lipolysis and lipogenesis, but also
in cell survival, apoptosis and cancer [3,5,31]. hGX sPLA2
induced robust TAG synthesis and LD formation in prolif-
erating MDA-MB-231 cells (Figures 2C and 2E), but the
effects on cell proliferation were modest (Additional file 1:
Figure S1A). On the other hand, although LD formation
was less pronounced in serum-deprived cells, the increase
in cell proliferation (Figure 1A) and, in particular, the re-
duction in apoptosis (Figure 1B) were more significant.
This suggests a mechanism by which the formed LDs pro-
vide energy, building blocks or signaling molecules to sus-
tain cell survival during energy stress [3,5,31]. Consistent
with this, although the LDs accumulated in hGX-treated
proliferating cells exhibited a minimal immediate prolifer-
ative effect (Figures 1A and Additional file 1: Figure S1A),
they conferred to the cells a marked survival advantage
during long-term starvation in the absence of the sPLA2
(Figure 3B). The hGX-induced LD accumulation was ac-
companied by increased levels of perilipin 2 mRNA,
while a decrease in its transcriptional level was observed
24 h after the cells were switched to serum-free medium
(Figure 7A). This is in line with its suggested role in
promoting TAG accumulation and blocking lipolysis
[3,59], as well as with the reported correlation between
TAG amount and perilipin 2 expression [57]. Since the
transcription of β-oxidation genes was elevated almost in
parallel with that of perilipin 2, it is conceivable that the
FFAs released by hGX from membrane phospholipids
are immediately partitioned between β-oxidation and
TAG synthesis, which may contribute to cell survival by
minimizing FFA toxicity [55]. However, since hGX-
induced LDs were sufficient to prevent cell death in the
absence of the sPLA2 (Figure 3B), the FFAs released fol-
lowing LD lipolysis are probably also involved in the
hGX-induced changes in cell metabolism and survival
[3,5]. Indeed, a cycle of FFA esterification and TAG lip-
olysis was required for FA-induced PPAR-mediated sig-
naling responsible for mitochondrial gene expression and
oxidative phosphorylation in cardiomyocytes [74]. Fur-
thermore, PPAR activation by lipolytic FFAs modulated
mitochondrial gene expression in brown adipose tissue,
matching FA oxidation with supply [75]. In line withthis, the hGX-induced alterations in gene expression
were augmented when proliferating cells were switched
to serum-free and sPLA2-free medium (Figure 7A),
suggesting that they form the basis for the metabolic adap-
tations that enable the positive effects of hGX on cell sur-
vival. Under these conditions, the pro-survival effects of
the pre-formed LDs were abolished if high concentrations
of etomoxir were used to block β-oxidation and LD break-
down (Figures 6D and 6E), suggesting that TAG lipolysis
followed by β-oxidation is critical for the pro-survival ef-
fects of hGX-induced LDs in MDA-MB-231 cells.
There is increasing evidence that CPT1 activity and β-
oxidation contribute to the metabolic adaptations that
enable cancer cell growth and survival [7]. Accelerated
β-oxidation protects cancer cells from cell death induced
by starvation or matrix detachment [6,8,10,35] by con-
tributing ATP and generating NADPH to counteract the
accumulation of ROS during metabolic stress [7-9,35].
Furthermore, the ability of etomoxir to block the posi-
tive effect of hGX on cancer cell survival (Figure 6) is in
line with recent studies showing that etomoxir-mediated
inhibition of β-oxidation leads to a reduction in cancer
cell proliferation and increased sensitivity to cell death
[9,35,53]. Additionally, apoptosis-induced mitochondrial
damage leads to LD formation due to inhibition of β-
oxidation and increased de novo lipid synthesis [76]. The
opposite alterations in FA oxidation and synthesis in-
duced by hGX sPLA2 in MDA-MB-231 cells may thus
counteract the apoptosis-related changes and avert cell
death. Therefore, the increased levels of CPT1A and
VLCAD in hGX-treated cells, together with the ability of
etomoxir to abrogate hGX-induced cell survival and in-
duce cell death in starved MDA-MB-231 cells, strongly
suggest that β-oxidation, and in particular CPT1 activity,
is necessary for the positive effects of hGX on MDA-MB-
231 cell proliferation and survival following serum
withdrawal.
The central metabolic regulator AMPK responds to
energy stress by suppressing ATP-consuming processes,
including FA, cholesterol and TAG synthesis [61,63],
while stimulating ATP-producing processes, such as gly-
colysis, mitochondrial biogenesis and β-oxidation
[3,8,61]. The acute effects of AMPK activation in most
cell types include a direct inactivation of ACC, leading
to suppression of FA synthesis, and also to a reciprocal
stimulation of CPT1 activity and β-oxidation due to re-
duction in malonyl-CoA levels [61]. Reduced expression
and activity of AMPK have been found in many cancers,
including primary breast tumors [77]. A metabolic
tumor suppressor role has been demonstrated recently
for AMPK in lymphoma, where it negatively regulates
the Warburg effect and limits cancer cell growth [78].
However, AMPK can also support cancer cell survival
and invasiveness [8,60], suggesting that its role in cancer
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physiological context [8,79]. In this study, we show that
the activity of hGX sPLA2 in invasive breast cancer cells
leads to the activation of AMPK, suggesting that the kin-
ase supports the pro-tumorigenic metabolic alterations
induced by hGX sPLA2. Elevated phosphorylation of
AMPK was detected in hGX-treated cells after 48 h of
cell proliferation (Figures 8A and 8B) when neutral lipid
accumulation reached maximal levels (Figure 2C) and
the gene expression changes were significant (Figure 7A).
Furthermore, etomoxir and triacsin C, which both atten-
uated hGX-induced LD formation, also prevented hGX-
induced AMPK activation (Figures 8A and 8B). This
suggests that the energy stress caused by rapid cell
growth and proliferation combined with extensive FA
activation, TAG synthesis and LD biogenesis in hGX-
treated MDA-MB-231 cells leads to AMPK activation
[29]. Accordingly, by mimicking cellular low energy sta-
tus and inducing a several-fold higher increase in the
level of phosphorylated AMPK relative to hGX (Figures 8A
and 8B), the AMPK activator AICAR completely pre-
vented hGX-induced LD formation (Figure 8C). This is
consistent with the previously reported strong cytostatic
effect of AICAR on MDA-MB-231 cells caused by sup-
pression of DNA, protein and lipid synthesis [64]. It is
thus possible that one of the important roles of AMPK in
hGX-treated cells is to restore the energy balance by
preventing further LD formation, by suppressing TAG
synthesis, by phosphorylating glycerol-3-phosphate acyl-
transferase (GPAT) [63], and by stimulating lipolysis, pre-
sumably by activating adipose triglyceride lipase (ATGL/
PNPLA2) [3,62], as well as β-oxidation. Apart from these
immediate effects on lipid metabolism, the observed long-
lasting transcriptional adaptations induced by hGX in
MDA-MB-231 cells (Figure 7A) could also be mediated by
AMPK. Namely, AMPK blocks SREBP-1 activity by direct
phosphorylation [80] or through inhibition of mTOR [50],
thus suppressing the transcription of its target genes, in-
cluding ACACA, FASN and SCD [4], but also lowering
SREBP-1 expression by reducing its auto-loop regulation
[80]. Additionally, hGX-released polyunsaturated FAs may
directly suppress the expression of SREBP-1 and its target
genes [34], including FASN and SCD, whose inhibition has
been shown to induce AMPK activation [4]. Also, elevated
AMPK activity may induce the expression and activity of
peroxisome proliferator-activated receptor-γ co-activator
1α (PGC1α) [7,61] to stimulate mitochondrial biogenesis
and the transcription of β-oxidation genes, such as those
encoding CPT1A and VLCAD. Similarly to the effects of
hGX in MDA-MB-231 cells, increased rates of β-
oxidation associated with AMPK phosphorylation, eleva-
tion of CPT1A mRNA and a decrease in lipogenesis due
to inactivation of ACC have recently been implicated in
the adipocyte-induced survival and metastasis of ovariancancer cells [60]. Importantly, it has been shown that acti-
vation of AMPK in cancer cells during energy stress en-
ables cell survival by blocking lipid synthesis through
inactivation of ACC and elevating β-oxidation-dependent
NADPH production to restore the redox balance [8]. Our
results indicate that AMPK activation also supports sur-
vival of MDA-MB-231 cells, since AICAR displayed a
strong anti-apoptotic effect in these cells (Figure 8E).
Thus, the activation of AMPK by hGX in proliferating
cells implicates AMPK in the coordination of the adapta-
tion of MDA-MB-231 cell metabolism to the FAs de-
rived from hGX membrane hydrolysis. Its association
with the hGX sPLA2-induced LD formation and cell sur-
vival, however, remains to be confirmed.
Our results with etomoxir and bezafibrate, modulators
of β-oxidation, suggest that β-oxidation supports the
process of hGX-induced LD biogenesis in MDA-MB-231
cells, regardless of their metabolic and proliferative status
(Figures 6A and 6C). It is, however, not clear how β-
oxidation can support LD formation. Presumably, elevated
β-oxidation may provide ATP and NADPH [7] for the en-
ergetically expensive process of LD formation [29], which,
besides TAG synthesis, also requires alterations in FA,
cholesterol and phospholipid synthesis and remodeling
[30]. Although the simultaneous activity of FA synthesis
and oxidation is controversial [7], a high β-oxidation flux
could contribute to the cytosolic pool of acetyl-CoA mole-
cules for de novo FA synthesis. Thus, despite the increased
level of FFAs released by the sPLA2 from phospholipids
and from TAGs through lipolysis, a low level of FA syn-
thesis is probably still necessary for maintaining the
proper FA composition of cell membranes and the mem-
branes of LDs, in particular in proliferating cells [1,30].
Additionally, hGX may stimulate a cycle of FA esterifica-
tion and lipolysis, as suggested for OA in MDA-MB-231
cells [29,42]. Since FA/TAG cycling requires high ACS ac-
tivity, at the expense of ATP, to provide a continuous sup-
ply of FA-CoA, it may also contribute to the observed
hGX-induced activation of AMPK [29]. In line with this,
besides etomoxir, the ACS inhibitor triacsin C also par-
tially blocked hGX-induced LD formation (Additional
file 5: Figure S4) and AMPK activation (Figures 8A and 8B)
in proliferating cells. We may thus speculate that, by
supplying FFAs, hGX stimulates β-oxidation that in turn
supports the anabolic branch of FA/TAG cycling,
resulting in net LD accumulation and thus filling the
LD energy reserves that can be used to support cell sur-
vival. Interestingly, recent studies revealing that mito-
chondria form contact sites with nascent LDs and
participate in phospholipid and TAG synthesis during
their biogenesis [30] are in line with a possible associ-
ation between β-oxidation and LD formation. It is thus
likely that hGX sPLA2 modulates the balance between the
catabolic branch of glycerolipid metabolism, including
Pucer et al. Molecular Cancer 2013, 12:111 Page 17 of 23
http://www.molecular-cancer.com/content/12/1/111TAG lipolysis and β-oxidation, and the anabolic processes,
such as de novo FA synthesis, phospholipid remodeling
and TAG synthesis. sPLA2 phospholipid hydrolysis, which
may feed a variety of lipids into both branches, would thus
induce metabolic alterations that lead to net LD accumu-
lation and enable the pro-survival activity of hGX in
MDA-MB-231 cells during prolonged serum deprivation.
The metabolic transformations induced by hGX sPLA2
in the highly invasive breast cancer cells, that include in-
creased accumulation of cytosolic LDs, up-regulated β-
oxidation and suppressed lipogenesis, resemble the effects
of omental fat pad adipocytes that provide lipids for ovar-
ian cancer cells to enable their growth and survival at the
metastatic site [60]. Interestingly, when MDA-MB-231
and T-47D cells were exposed to the same primary human
fat pad adipocytes they also accumulated large amounts of
LDs and displayed increased invasive properties [60]. This
suggests that the effects of hGX sPLA2 identified in this
study could be pathophysiologically relevant. hGX sPLA2
may be secreted not only from breast cancer cells, but also
from different cells in the tumor microenvironment, in-
cluding inflammatory cells [12] and adipocytes [34], at pri-
mary tumor sites or at lipid-rich metastatic sites. It may
then act in an autocrine or paracrine manner on cellular
and extracellular phospholipids [12] to alter the availability
of FFAs and induce metabolic transformations in cancer
cells to support their survival, growth and metastatic po-
tential. Furthermore, alterations in lipid metabolism and
lipid accumulation within LDs in non-adipose tissue have
been recognized as a major risk factor for the develop-
ment of cancer and also other chronic diseases, such as
metabolic syndrome, cardiovascular disease and diabetes
[4,31]. Thus, the present study raises the possibility that
modulation of cellular lipid metabolism by hGX and other
sPLA2s may also contribute to some of these debilitating
diseases.
Conclusions
Several sPLA2s have been previously shown to affect the
fate of cancer and other cells, however, their mecha-
nisms of action at the cellular level are still unclear, have
not been causally linked to eicosanoid or other lipid sig-
naling, and have never been related to lipid droplets or
alterations in basic lipid metabolism. We show in this
study that hGX sPLA2, through the products of its en-
zymatic activity, induces LD formation and alters lipid
metabolism in triple negative breast cancer cells, stimu-
lating their proliferation and prolonging cell survival
during growth factor deprivation. We provide evidence
that the pro-tumorigenic effects of hGX are associated
with activation of AMPK, suppression of lipogenesis and
activation of β-oxidation, which is critical for the sur-
vival of hGX-treated MDA-MB-231 cells, most probably
by contributing to the restoration of the energy andredox balance [1,7]. The results also suggest the intri-
guing possibility that hGX-induced elevated β-oxidation
also supports the anabolic branch of FA/TAG cycling,
leading to a net LD accumulation that in turn enables
prolonged cell survival. Finally, the ability of hGX sPLA2
to act as a modulator of basic lipid metabolism and can-
cer cell survival is established. This could have import-
ant implications in elucidating the role of hGX and
other sPLA2s, such as hGV and hGIII, in cancer and hu-
man pathophysiology in general.
Materials and methods
Materials
Cell cultures (MDA-MB-231, T-47D, MCF7, SK-BR-3,
MCF-10A) and culture media (RPMI-1640, MEM,
McCoy’s 5A) were from ATCC (USA). Mammary epithe-
lial cell growth medium (MEGM) was from Lonza (USA)
and fetal bovine serum (FBS), Dulbecco’s phosphate-
buffered saline (DPBS), TrypLe Select and Opti-MEM
from Life Technologies (USA). Varespladib (LY315920)
was from Selleck Chemicals (USA) and fatty acid-free
(FAF) BSA (#A7511), Nile red, tetramethylrhodamine, me-
thyl ester (TMRM), etomoxir sodium salt hydrate,
bezafibrate and S32826 from Sigma-Aldrich (USA). YO-
PRO-1 iodide was from Life Technologies (USA); oleic acid
and rapamycin were from Merck (Germany), 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR)
and pyrrolidine-2 (also called pyrrophenone) were from
Cayman Chemical (USA), BrP-LPA was from Tebu-Bio
(France), indomethacin and triacsin C were from Enzo Life
Sciences (Switzerland). The phospho-AMPKα (Thr172)
mAb (#2535), AMPKα mAb (#2603), acetyl-CoA carboxyl-
ase mAb (#3676), phospho-Akt (Ser473) mAb (#4060), Akt
(pan) mAb (#4691) were from Cell Signaling Technology
(USA). The SREBP-1 (#sc-367) and VLCAD antibodies
(#sc-271225) were from Santa Cruz Biotechnology (USA),
β-actin antibody (NB600-532) was from Novus Biologicals
(UK). AZ-1 was provided by Prof. Michael H. Gelb (Uni-
versity of Washington, Seattle, USA) and corresponds to
compound 22 in Connolly et al. [48]. The recombinant
wild-type mammalian group IIA, V and X sPLA2s, the
catalytically inactive mutant (H48Q) of mouse group X
sPLA2 and the V31W mutant of the snake venom sPLA2
AtxA were prepared as described [13,46,81]. All other
chemicals were of at least analytical grade and purchased
from Sigma-Aldrich (USA) and Serva (Germany).
Cell lines and culture conditions
The MDA-MB-231 and T-47D cell lines were cultured
in RPMI-1640 medium supplemented with 10% FBS,
and with 0.2 Units/ml of bovine insulin (Sigma-Aldrich,
USA) in the case of the T-47D cell line. MCF7 cells were
cultured in MEM with 10% FBS and 0.01 mg/ml bovine in-
sulin, SK-BR-3 cells in McCoy's 5A medium supplemented
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presence of 100 ng/ml cholera toxin (Sigma-Aldrich,
USA) and without the supplement GA-1000 (Lonza,
USA). In experiments using serum-deprived cells, FBS
was replaced by 0.02–0.5% FAF BSA. Pharmacological
agents were added to cell culture media at an appropriate
concentration 1 h prior to the addition of recombinant
sPLA2 and were present in the media for the duration of
the treatment. The sPLA2 inhibitor varespladib was incu-
bated with the enzyme in the appropriate medium at a
concentration of 50 μM for 15 min and the mixture then
added to cells. In experiments longer than 48 h, culture
media was replenished by adding an aliquot from the
stock inhibitor solution. Oleic acid was complexed to 0.5%
FAF BSA or 10% FBS in culture medium before addition
to cell culture.
Real-time quantitative PCR (qPCR)
Cells were seeded in 6-well plates at a concentration of
1.5 × 105 cells/well. 24 h later they were treated with 1
nM hGX in complete culture medium and incubated for
an additional 48 h. The cells were washed with DPBS
and incubated for an additional 48 h in serum-free
medium containing 0.02% FAF BSA and harvested at de-
sired time-points. Total RNA was extracted from cell ly-
sates using TRIzol reagent (Life Technologies, USA)
according to the manufacturer’s instructions and quanti-
fied using a NanoDrop Spectrophotometer (Thermo Sci-
entific, Rockford, USA). RNA quality was assessed using
an Agilent 2100 Bioanalyzer (USA). First strand cDNA
was synthesized from 1 μg of RNA using the High Cap-
acity cDNA Reverse Transcription Kit with RNase In-
hibitor (Life Technologies, USA) and random primers,
according to the manufacturer’s instructions. qPCR reac-
tions were carried out for all genes of interest and two
reference genes (Additional file 2: Table S1) in each sam-
ple using LightCycler 480 SYBR Green I Master (Roche
Applied Science, Germany) chemistry on a LightCycler
480 instrument (Roche Applied Science, Germany). All
reactions were performed in a total volume of 5 μl and
contained 10 ng RNA equivalent cDNA and 250 nM of
each set of primers. Thermal cycles were set at 95°C for
10 min, followed by 45 cycles of 95°C for 10 s, 60°C for
15 s and 72°C for 20 s. No template control reactions
were included in the assays. PCR efficiencies were at
least 80% for all primer pairs and a single melting peak
was observed for each primer pair. Relative gene expres-
sion was calculated upon normalization to two reference
genes and corrected for primer-specific PCR efficiency
as described previously [82].
Transient transfection
The full-length cDNA coding for hGX sPLA2 [83] was
cloned into the pcDNA3.1/D-V5-His-TOPO expressionvector (Life Technologies, USA) according to manufac-
turer’s instructions. The hGX H48Q mutant was gener-
ated using the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technologies, USA) following manufacturer’s
instructions. For transient transfection, MDA-MB-231
cells were seeded in 24-well plates at a concentration of
1.5 × 105 cells/well and incubated for 24 h in complete
culture medium. Cells were transfected with 0.8 μg/well of
plasmid DNA using 1.6 μl/well Lipofectamine 2000 (Life
Technologies, USA) according to manufacturer’s in-
structions. Cell proliferation was measured 48 h after
transfection. For determination of cell survival after
serum-deprivation, cells were washed twice with serum-
free medium containing 0.05% FAF BSA 24 h post-
transfection, incubated in the same medium for an
additional 96 h and analyzed using the TMRM/YO-
PRO-1 cell death assay.
Cell proliferation assay
Cells were plated in complete medium in 24-well culture
plates at 6 × 104 cells per well. After 24 h the medium
was replaced with serum-free medium containing 0.1%
BSA and the cells incubated for 48 h. Quiescent cells
were then treated for 24 h with 10 nM hGX in serum-free
medium with 0.1% BSA. The 5-ethynyl-2’-deoxyuridine
(EdU) nucleoside analog was added at a final concentra-
tion of 10 μM for the last 6 h of cell treatment. Floating
and attached cells were harvested together and stained
with Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay
Kit (Life Technologies, USA) according to manufacturer's
instructions. RNase A (Sigma-Aldrich, USA) was added to
a final concentration of 200 μg/ml and cellular DNA was
stained with 7-AAD (Life Technologies, USA) added to a
final concentration of 10 μg/ml for 1 h. Samples were ana-
lyzed on a FACSCalibur flow cytometer equipped with a
488-nm Ar-ion laser using the CellQuest software (Becton
Dickinson, USA). The logarithmic Alexa 488 fluorescence
signal was collected using the FL-1 filter (530/30) and lin-
ear 7-AAD fluorescence signal was collected using the FL-
3 filter (650LP). Samples were prepared in duplicate with
analysis on 2 × 104 events per sample.
TMRM/YO-PRO-1 apoptosis assay
For survival assays, cells were seeded in 24-well culture
plates at a concentration of 6 × 104 cells/well (MDA-
MB-231, T-47D), 3 × 104 cells/well (MCF-10A) or 1 ×
105 cells/well (MCF7, SK-BR-3). After 24 h, cells were
placed in their respective serum-free media with 0.02%
FAF BSA for an additional 24 h, and treated with sPLA2
and effectors in serum-free medium with 0.02% FAF
BSA for an additional 96 h (MDA-MB-231), 120 h
(MCF7, MCF-10A, SK-BR-3) or 168 h (T-47D) and the
cells harvested for analysis. To test the effect of pre-
formed LDs on cell survival, MDA-MB-231 cells were
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104 cells/well. Twenty-four hours later, the medium was
discarded and 1 nM hGX in complete culture medium
was added for an additional 48 h. hGX was removed by
washing the cells twice with DPBS, the cells serum-
starved in the presence of 0.02% FAF BSA for an
additional 96 h and then harvested for analysis. The
percentage of apoptotic cells was determined by TMRM/
YO-PRO-1 staining using an adapted version of the
protocol described previously [84]. Floating and adher-
ent cells were combined, pelleted, resuspended in 100 μl
of 150 nM TMRM solution in DPBS and incubated for
15 min in the dark at room temperature. YO-PRO-1
iodide was added to a final concentration of 50 nM for
an additional 10 min. The cell suspension was diluted
with 200 μl 0.1% BSA in DPBS and analyzed by flow
cytometry. The YO-PRO-1 and TMRM fluorescence sig-
nals were collected using FL-1 (530/30) and FL-3
(650LP) filters, respectively. TMRM negative and YO-
PRO-1 positive cells were considered apoptotic. Samples
were prepared in duplicate and analyzed on 2 × 104 events
per sample.
Nile red staining of lipid droplets
Cells were seeded in complete culture medium in 24-
well plates at a concentration of 3 × 104 cells/well
(MDA-MB-231), 6 × 104 cells/well (T-47D) or 105 cells/
well (MCF7). Twenty-four hours later, cells were treated
with hGX in complete culture medium and incubated
for at least 24 h prior to Nile red staining. For LD ana-
lysis of serum-deprived cells, the cells were treated as
described above for the apoptosis assay. Cells were
harvested, and the pellet resuspended in 500 μl of 1 μg/
ml Nile red solution in DPBS and incubated in the dark
for 10 min. Immediately after staining, the cells were an-
alyzed by flow cytometry. The logarithmic fluorescence
signal was collected using the FL-1 filter (530/30). Sam-
ples were prepared in duplicate and analyzed on 2 × 104
events per sample.
Triglyceride assay
MDA-MB-231 cells were seeded on 10-cm plates at a
concentration of 1 × 106 cells/well, grown for 24 h and
treated with 1 nM hGX in complete culture medium for
the next 48 h. The cells were harvested using a cell
scraper, pelleted and cell lysates prepared for analysis of
TAG content using the Triglyceride Fluorometric Assay
Kit (Cayman Chemicals, USA) according to manufac-
turer’s instructions.
Fluorescence microscopy
MDA-MB-231 cells were seeded on glass coverslips in
6-well plates at a density of 1.5 × 105 cells/well, grown
for 24 h and treated with 1 nM hGX in complete culturemedium for the next 48 h. The cells were washed with
DPBS and fixed with 4% paraformaldehyde in DPBS for
30 min, washed again, and stained with 1 μg/ml Nile
red solution in DPBS for 10 min. After an additional
washing step with DPBS, they were mounted on micro-
scope slides using ProLong Gold Antifade Reagent with
DAPI (Life Technologies, USA). The images were ac-
quired using a Zeiss Axio Observer Z1 inverted micro-
scope with a plan apochromatic objective (40×, 0.95
NA; Carl Zeiss, Germany), using 470/40 excitation and
525/50 emission filters for the Nile red signal and G365
excitation and 445/50 emission filters for the DAPI
signal.Immunoblot analysis
Cell lysates were prepared by scraping adherent cells
into 2× reducing protein-loading buffer (0.125 M Tris-
HCl, pH 6.8; 4% SDS, 0.02% bromophenol blue, 20% gly-
cerol, 100 mM DTT; Protein Loading Buffer Pack,
Thermo Scientific, USA) with the addition of Halt Phos-
phatase Inhibitor Cocktail (Thermo Scientific, USA) and
EDTA-Free Halt Protease Inhibitor Cocktail (Thermo
Scientific, USA). The proteins were denatured by heating
at 95°C for 10 min and total protein content determined
using the Pierce 660 nm Protein Assay in the presence
of 50 mM Ionic Detergent Compatible Reagent (Thermo
Scientific, USA), using BSA as standard. Aliquots of 5–15 μg
of total protein were separated on a 7.5% or 10% SDS-
PAGE gel and proteins transferred to a polyvinylidene
difluoride (PVDF) membrane (Millipore, USA). After a 1
h-blocking step in 5% BSA in TBS or in 1% Western
Blocking Reagent in TBS (Roche Applied Science,
Germany), the membrane was incubated overnight at 4°C
with gentle shaking in a solution of appropriately diluted
primary antibody in 2.5% or 5% BSA in TBS/0.1% Tween-
20 (TBST) or in 0.5% Western Blocking Reagent in TBS.
After three washing steps in TBST, membranes were incu-
bated with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (Cell Signaling Technology or Jackson
ImmunoResearch Laboratories, USA). After three add-
itional washing steps, the proteins bands were visualized
using Lumi-Light Western Blotting Substrate (Roche Ap-
plied Science, Germany) and Amersham Hyperfilm ECL
films (GE Healthcare, UK). Band density was quantified by
densitometric analysis using ImageJ software (National
Institute of Health, USA).Statistical analysis
Data are presented as means ± SD. Prism software
(GraphPad Software, USA) was used for statistical ana-
lysis, using Student’s t-test and one-way ANOVA with
Bonferroni adjustment for multiple comparisons. P values
lower than 0.05 were considered statistically significant.
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Additional file 1: Figure S1. hGX and mGX stimulate the proliferation
of breast cancer cells in an enzymatic activity-dependent manner. (A)
MDA-MB-231 cells were cultured in complete medium in the presence of
indicated concentrations of hGX for 72 h. (B) After serum deprivation for
48 h, MDA-MB-231 cells were treated with recombinant mGX, or its
enzymatically-impaired mutant H48Q, at the indicated concentrations in
serum-free medium containing 0.1% BSA for 24 h. Cell proliferation (A, B)
was determined using the EdU incorporation assay on fixed cells with
additional 7-AAD staining. The nucleoside analog EdU was added to a
final concentration of 10 μM for the last 4 h (A) or 6 h (B) of treatment.
(C) After serum deprivation for 24 h, MDA-MB-231 cells were treated with
recombinant hGX (10 nM) in serum-free medium containing 0.02% FAF
BSA for 96 h in the presence or absence of the pan-sPLA2 inhibitor
varespladib (Var) at a final concentration of 50 μM. After 96 h, the
adherent cells were washed and the number of viable cells was
determined by trypan blue exclusion using a hemocytometer. Values are
means ± SD of three experiments and results that are statistically
significant over control samples are indicated (*, P < 0.05; one-way
ANOVA with Bonferroni adjustment).
Additional file 2: Table S1. Primers used in qPCR analysis. Table S2.
Determination of hGX sPLA2 enzymatic activity in culture media of
transfected MDA-MB-231 cells. MDA-MB-231 cells grown for 24 h in
complete culture medium were transiently transfected with empty vector
and plasmids encoding the wild-type hGX or catalytic-site mutant hGX
(H48Q). The cells were then cultured in complete medium for an
additional 72 h (FBS). Alternatively, the cells were washed 24 h post
transfection and incubated in serum-free medium containing 0.05% FAF
BSA for an additional 48 h (BSA). The concentration of hGX secreted in
the culture medium at indicated time points was determined with the
in vitro sPLA2 enzymatic assay using [
3H]oleic acid-radiolabeled E. coli
membranes as described in the Supplemental Method. Abbreviations: nd,
not detected.
Additional file 3: Figure S2. Treatment of proliferating MDA-MB-231
cells with hGX results in increased cell granularity. MDA-MB-231 cells
were grown in complete medium for 24 h, then treated with hGX
(100 nM) in complete medium for 48 h. The cells were harvested,
resuspended in DPBS and their morphology analyzed by flow cytometry.
Forward scatter (FSC) and side scatter (SSC) parameters were analyzed
revealing a considerable increase in mean cell granularity (SSC) of hGX-
treated cells (B) in comparison with control cells (A), indicating
accumulation of cytoplasmic LDs. A representative scatter diagram is
shown.
Additional file 4: Figure S3. hGX sPLA2 releases oleic acid from MDA-
MB-231 cells. MDA-MB-231 cells were labeled with [3H]OA and grown in
complete medium in the presence of hGX (1 nM) for 24 h. [3H]OA release
to the medium was determined as described in Supp. Methods. Values
on the graph are means ± SD of three independent experiments
performed in duplicate. Statistical significance is indicated (**, P = 0.0435;
Student's t-test).
Additional file 5: Figure S4. The effects of various pharmacological
agents on hGX-induced changes in LD formation and survival of MDA-
MB-231 cells. (A) MDA-MB-231 cells were grown in complete medium for
24 h, then treated with hGX (1 nM) in complete medium for 48 h in the
presence or absence of indomethacin (Indo; 50 μM), pyrrolidine-2 (Pyr-2;
5 μM), AZ-1 (10 μM), rapamycin (Rapa; 1 μM), S32826 (10 μM), BrP-LPA
(10 μM), triacsin C (TrC; 2 μM). Levels of LDs were determined by Nile red
staining and normalized to control samples. LD content was significantly
greater after hGX treatment, in spite of the presence of inhibitors.
Indomethacin, rapamycin and triacsin C significantly attenuated the hGX-
induced increase in LD content. Pyrrolidine-2 alone caused an increase in
LD content over control values (#, P < 0.001; one-way ANOVA with
Bonferroni adjustment) and, in combination with hGX, even potentiated
its ability to induce LDs. (B) Quiescent MDA-MB-231 cells were treated
with hGX (10 nM) in serum-free medium containing 0.02% FAF BSA for
96 h in the presence or absence of indomethacin (50 μM) and of
pyrrolidine-2 (1 μM). The percentage of apoptotic cells was determined
by the TMRM/YO-PRO-1 apoptosis assay. Indomethacin and pyrrolidine-2did not attenuate the hGX-induced pro-survival effect, though
pyrrolidine-2 exerted some mild toxicity in serum-starved cells. Values are
means ± SD of at least two experiments and results that are statistically
significant over control samples are indicated (*, P < 0.05; **, P < 0.01;
***, P < 0.001; one-way ANOVA with Bonferroni adjustment).
Additional file 6: Figure S5. Non-toxic concentrations of etomoxir
prevent the hGX-induced pro-survival effect. Serum-starved MDA-MB-231
cells were treated with hGX (10 nM) in serum-free medium containing
0.02% FAF BSA for 96 h in the presence or absence of different
concentrations of etomoxir (Eto) as indicated. The percentage of
apoptotic cells was determined by the TMRM/YO-PRO-1 apoptosis assay.
The pro-survival effect of hGX was abolished in the presence of 20 μM
and 50 μM concentrations of etomoxir, which were not toxic to control
MDA-MB-231 cells. Values are means ± SD of three experiments
performed in duplicate and results that are statistically significant over
control samples are indicated (*, P < 0.05; ***, P < 0.001; one-way ANOVA
with Bonferroni adjustment).
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